TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05217472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravaglimab
Description: Intravenous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravagalimab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection
Study: NCT03505762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02950506

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation Therapy
Description: The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.). Cogmed is a targeted computerized training program that has been shown to improve working memory and attention. (Spencer-Smith 2015).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cognitive Remediation Therapy
Description: The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.). Cogmed is a targeted computerized training program that has been shown to improve working memory and attention. (Spencer-Smith 2015).
Study: NCT00666744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Mediated Exercise Therapy
Description: 35 minutes of lower limb exercises to be completed by the person with stroke on a daily basis with the assistance of their family for a period of 8 weeks.
Study: NCT03280329

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Generalized Music therapy
Description: Patients will receive broadcasted music via speakers in their room from 7am to 11pm, from admission to discharge

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Music therapy
Description: Patients will receive music via earphones after specific music therapist advice, for 2 hours per day, from admission to discharge
Study: NCT03505762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary correlative

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary correlative

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT01508312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin (SGN-35)
Description: Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with persistent abnormalities on FDG-PET/CT following 2 cycles of brentuximab vedotin will receive 2 cycles of augmented ICE. The first cycle of augmented ICE will be initiated 7-14 days after the last dose of SGN-35. FDG-PET/CT will be repeated within 7-14 days following the second cycle of augmented ICE. Stem cell mobilization can be performed following the first or second cycle of augmented ICE.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin (SGN-35)
Description: Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. Patients with normalization of FDG-PET/CT and negative bone marrow biopsies following 2 cycles of brentuximab vedotin will undergo stem cell mobilization in preparation for ASCT.
Study: NCT03150329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT02443077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Transplantation
Description: Undergo autologous hematopoietic progenitor cells or bone marrow transplant

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Bone Marrow Transplantation
Description: Undergo autologous hematopoietic progenitor cells or bone marrow transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous hematopoietic progenitor cells or bone marrow transplant
Study: NCT02085811

Intervention type: OTHER
Intervention: radiography standard
Study: NCT02443077

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous hematopoietic progenitor cells or bone marrow transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV
Study: NCT05786170

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: diffusion-weighted magnetic resonance imaging
Study: NCT02421874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wraparound Team Monitoring System electronic health record
Description: Wraparound Team Monitoring System (Wrap-TMS) is a web-based, electronic behavioral health information system (EBHIS) for the most widely implemented care coordination model in children's behavioral health, the wraparound process

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education about fidelity maintenance and monitoring
Description: As an active comparator, we will educate practitioners randomized to the control condition about the importance of maintaining fidelity and monitoring fidelity and progress via a 3 hour training.
Study: NCT02443077

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT03785080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: restart NOAC very early
Description: withhold NOAC less than 24 hours Post OGD

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: restart NOAC early
Description: withhold NOAC for 72 to 84 hours Post OGD
Study: NCT03457298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ossix Volumax
Description: Ossix Volumax is intended to be used for Lateral ridge augmentation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDBA with collagen membrane
Description: freeze-dried bone allograft (FDBA) with collagen membrane
Study: NCT03693872

Intervention type: DRUG
Group type: OTHER
Intervention: Apomorphine
Description: Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient

Intervention type: DRUG
Group type: OTHER
Intervention: Dopaminergic Agonist + Apomorphine
Description: Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient and associated with dopaminergic agonists
Study: NCT01088425

Intervention type: OTHER
Intervention: Observation
Description: Alberta infant motor scale~Griffiths test~Kauffmann ABC

Intervention type: OTHER
Intervention: Observation
Description: Alberta infant motor scale~Griffiths test~Kauffmann ABC

Intervention type: OTHER
Intervention: Observation
Description: Alberta infant motor scale~Griffiths test~Kauffmann ABC
Study: NCT02849769

Intervention type: DEVICE
Intervention: Implant of an MR-conditional Tachy device system
Study: NCT04837612

Intervention type: OTHER
Intervention: No intervention nor exposure
Description: As an observational study, no intervention nor exposure is interested.
Study: NCT03116880

Intervention type: PROCEDURE
Intervention: Endovascular aortic repair
Description: Endovascular aortic repair
Study: NCT03593694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TECH DM-BAT
Description: Multi-component, high intensity intervention, technology delivered, diabetes-modified behavioral activation treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TECH DMBAT Active Comparator
Description: Technology delivered diabetes education and home tele monitoring

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TECH DMBAT Other
Description: Technology delivered diabetes education
Study: NCT01220219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 82.5 mg
Description: Two tablets of 82.5 mg controlled release (administered concurrently) once daily for four days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 165 mg
Description: 165 mg controlled release tablet administered once daily for four days.

Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin immediate release, 75mg
Description: 75 mg immediate release capsule administered every 12 hours for four days
Study: NCT03853694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen
Description: Intrathecal injection of 50 mcg Duramorph + EXPAREL administered via TAP infiltration + multi-modal pain regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150 mcg Duramorph + multi-modal pain regimen
Description: Intrathecal injection of 150 mcg Duramorph + multi-modal pain regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel TAP + multi-modal pain regimen
Description: EXPAREL administered via TAP infiltration + multi-modal pain regimen.
Study: NCT05125653

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Fluorescent Laparoscopic Cholangiography
Description: Indocyanine Green Fluorescent Cholangiography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: White Light
Description: Performing the laparoscopic cholecystectomy and identifying the biliary structures under the conventional white light
Study: NCT03792503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500 mg Po qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexe 500 mg/m2 d1×q3w
Study: NCT02568436

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: low level laser therapy is intended to accelerate tooth movement
Study: NCT04462237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root coverage procedures
Description: Treatment of multiple adjacent gingival recession using a coronally advanced flap
Study: NCT02443077

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melphalan
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT02305147

Intervention type: OTHER
Intervention: Clinical, biological and imaging followup
Description: Assessment of motor and non motor signs every 12 months. Imaging and blood, cerebral fluid, stools and skin samples for identification of biomarkers of disease phenotype and progression.

Intervention type: OTHER
Intervention: Clinical, biological and imaging followup
Description: Assessment of motor and non motor signs every 12 months. Imaging and blood, cerebral fluid, stools and skin samples for identification of biomarkers of disease phenotype and progression.
Study: NCT05047965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dixon MRI
Description: Undergo Dixon MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo standard MRI
Study: NCT03579017

Intervention type: DIAGNOSTIC_TEST
Intervention: ECAS-N
Description: All participants included will be tested with the ECAS-N

Intervention type: DIAGNOSTIC_TEST
Intervention: ECAS-N
Description: All participants included will be tested with the ECAS-N

Intervention type: DIAGNOSTIC_TEST
Intervention: ECAS-N
Description: All participants included will be tested with the ECAS-N

Intervention type: DIAGNOSTIC_TEST
Intervention: MoCA
Description: All included patients With ALS will be tested With the MoCA
Study: NCT03285763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive 1200 milligrams (mg) of atezolizumab administered by intravenous infusion on Day 1 of every 3-week cycle until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
Study: NCT04927091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integration of HIV and PWID services
Description: Co-location of clinical services for HIV and PWID patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integration of HIV and PWID services
Description: Co-location of clinical services for HIV and PWID patients
Study: NCT03702218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct Acting Antivirals
Description: Patients who are given organ transplants from donors that are Ab positive and NAT negative or Ab positive and NAT positive for Hepatitis C will be treated with direct acting antivirals after transplant if they become NAT+ for hepatitis C.~Interventions as follows.~Liver Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~* Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR\>30~* Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR\>30~Kidney Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~* Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR\>30

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct Acting Antivirals
Description: Patients who are given organ transplants from donors that are Ab positive and NAT negative or Ab positive and NAT positive for Hepatitis C will be treated with direct acting antivirals after transplant if they become NAT+ for hepatitis C.~Interventions as follows.~Liver Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~* Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR\>30~* Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR\>30~Kidney Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~* Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR\>30

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Direct Acting Antivirals
Description: Patients who are given organ transplants from donors that are Ab positive and NAT negative or Ab positive and NAT positive for Hepatitis C will be treated with direct acting antivirals after transplant if they become NAT+ for hepatitis C.~Interventions as follows.~Liver Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~* Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR\>30~* Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR\>30~Kidney Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~* Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR\>30
Study: NCT01980771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BTWB intervention
Description: Men work in groups to complete a intervention that takes approximately two hours to complete.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cancer prevention and screening
Description: Men are provided health education about cancer screening and prevention
Study: NCT03498794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteral stent
Description: Patients will be randomized into 2 groups:~Group (A): 75 patients with the use of ureteral stent. Group (B): 75 patients with the use of PCN.~How the technique will be applied?~Technique of ureteral stent insertion:~The ureteral stent will be inserted retrograde by using flexible cystoscope.~Technique of PCN insertion:~Percutaneous nephrostomy will be performed in the angiography suite by a urologist with the patient under local anesthesia. All the patients will be given non-nephrotoxic antibiotics pre-operatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteral stent
Description: Patients will be randomized into 2 groups:~Group (A): 75 patients with the use of ureteral stent. Group (B): 75 patients with the use of PCN.~How the technique will be applied?~Technique of ureteral stent insertion:~The ureteral stent will be inserted retrograde by using flexible cystoscope.~Technique of PCN insertion:~Percutaneous nephrostomy will be performed in the angiography suite by a urologist with the patient under local anesthesia. All the patients will be given non-nephrotoxic antibiotics pre-operatively.
Study: NCT04009486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: Subjects will undergo whole body vibration (standing on a power plate device 3 times a week, for 30 minute sessions, for 6 weeks)
Study: NCT00313794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: 15 mg/kg IV q 3 months for 4 cycles in the absence of disease progression or unacceptable toxicity.
Study: NCT02478983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA Supreme
Description: The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Proseal
Description: The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
Study: NCT04462237

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root coverage procedures
Description: Treatment of multiple adjacent gingival recession using a coronally advanced flap
Study: NCT01339247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico
Description: Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico
Description: Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada
Description: Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada
Description: Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
Study: NCT03202238

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Conventional venepuncture without use of any venepuncture assistive device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Veinlite
Description: Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TenTaTorch
Description: Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue